NEW STUDY BY CDC AND ABT ASSOCIATES: INCREASED RISK OF COVID-19 AMONG FIRST RESPONDERS AND THEIR LOW VACCINATION RATES COULD THREATEN PUBLIC SAFETY

NEXT STORY
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
PREV STORY
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, ...

author_avatar
NASDAQ Market News

Oncology Startup Notable Labs Donates its First Pediatric Therapy to Repurposing Non-Profit

Notable Labs is donating commercial rights to price, manufacture and distribute pediatric leukemia drug ...

author_avatar
NASDAQ Market News

TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage ...

author_avatar
NASDAQ Market News